The P3H1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the human P3H1 gene in the Raji B lymphocyte cell line. This genetically heterogeneous pool provides a robust loss-of-function model for studying P3H1 in a lymphoid context, avoiding the limitations of single-cell clone selection. The cells are suitable for a range of functional assays and serve as a critical tool for dissecting P3H1-dependent mechanisms.
The Raji cell line is an Epstein-Barr virus (EBV)-positive lymphoblastoid cell line derived from a patient with Burkitt’s lymphoma. It grows in suspension and is widely employed as a model for B-cell malignancies and immunological studies. The cell line expresses characteristic B-cell surface markers such as CD19 and CD20, enabling immunophenotypic verification. Its hematopoietic origin provides a unique background to investigate non-canonical functions of P3H1 beyond collagen-producing connective tissue cells.
P3H1 encodes prolyl 3-hydroxylase 1, an enzyme that catalyzes the 3-hydroxylation of specific proline residues in nascent collagen type I ?? chains within the endoplasmic reticulum. This modification, occurring within a complex containing CRTAP and cyclophilin B (PPIB), is essential for collagen triple helix stability and secretion. P3H1 activity is modulated by upstream factors such as TGFB1, HIF1A, and ER stress signals, while downstream effects include proper collagen fibril formation and bone mineralization. P3H1 also interacts with BiP (HSPA5) and forms part of a broader collagen processing network alongside P4HA1, P4HA2, and the HSP47 chaperone.
Although Raji cells are not professional collagen-secreting cells, they do express collagen-modifying enzymes, and P3H1 may have functions independent of extracellular matrix assembly. Disruption of P3H1 in this B lymphocyte model can induce ER stress, alter chaperone interactions, and reveal unrecognized roles in hematological cell biology. This system thus offers a valuable platform to examine cell-type-specific consequences of P3H1 loss, potentially uncovering links between collagen hydroxylation defects and lymphoid cell physiology.
These polyclonal knockout cells are well-suited for applications including the investigation of P3H1 function in hematopoietic cells, the study of extracellular matrix-independent roles, and the use as a knockout control in assays targeting collagen modification. They also facilitate drug screening for osteogenesis imperfecta therapies in a lymphoid context. Representative experimental readouts include Western blotting for P3H1 protein, RT-qPCR for mRNA quantification, Sanger sequencing of the CRISPR target site, flow cytometry for B cell markers (CD19, CD20), as well as cell proliferation and apoptosis assays. For further details and customized services, please contact Ascent Research.
